Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials

BACKGROUND: Cilostazol overcomes high on-treatment platelet reactivity (HTPR) and reduces adverse cardiovascular (CV) outcomes after percutaneous coronary intervention (PCI). However, the role for triple antiplatelet therapy (TAPT) with cilostazol in addition to aspirin and clopidogrel after PCI is...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Bangalore, Sripal, Singh, Amita, Toklu, Bora, DiNicolantonio, James J, Croce, Kevin, Feit, Frederick, Bhatt, Deepak L
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2014
Assuntos:
Coronary Artery Disease
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4189225/
https://ncbi.nlm.nih.gov/pubmed/25332804
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/openhrt-2014-000068
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados